Elite HIV controllers: Myth or reality?

AIDS Reviews

Volumn 9, Issue 4, 2007, Pages 195-207

  Saksena, Nitin K ^a   Rodes, Berta ^b   Wang, Bin ^a   Soriano, Vincent ^b  

^a WESTMEAD HOSPITAL   (Australia)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Elite HIV controllers; HIV; Long term nonprogressors

Indexed keywords

ADENINE; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GAG PROTEIN; GAMMA INTERFERON; GUANINE; HLA B ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; NEF PROTEIN; POL PROTEIN; REV PROTEIN; TAX PROTEIN; TRANSACTIVATOR PROTEIN; UNINDEXED DRUG; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS RNA; VPR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DETERIORATION; DISEASE COURSE; DRUG EFFICACY; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFECTION CONTROL; INFECTION RATE; INFECTION RESISTANCE; INNATE IMMUNITY; PREVALENCE; PROVIRUS; REVIEW; VIRUS IMMUNITY; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CYTOSINE DEAMINASE; DISEASE PROGRESSION; HIV; HIV LONG-TERM SURVIVORS; HLA ANTIGENS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, NATURAL; VIRAL LOAD; VIRUS REPLICATION;

EID: 38749116607     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Goudsmit J, Bogaards J, Jurriaans S, et al. Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viremia. AIDS. 2002;16:791-3.
2. Birch M, Learmont J, Dyer W, et al. An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort. J Clin Virol. 2001;22:263-70.
3. Deacon N, Tsykin A, Solomon A, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science. 1998;270:988-91.
4. Gray L, Churchill M, Sterjovski J, et al. Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long-term survivors infected from a single source. J Virol. 2007;4:75.
5. Learmont J, Geczy A, Mills J, et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med. 1999;340:1715-22.
6. Rodes B, Toro C, Jimenez V, Soriano V. Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2. Clin Infect Dis 2005;41:e19-21.
7. Wang B, Spira T, Owen S, Lal R, Saksena N. HIV-1 strains from a cohort of American subjects reveal the presence of a V2 region extension unique to slow progressors and nonprogressors. AIDS. 2000;14:213-23.
8. Wang B, Mikhail M, Dyer W, Zaunders J, Kelleher A, Saksena N. First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection. Virology. 2003;312:135-50.
9. Lambotte O, Boufassa F, Madec Y, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis. 2005;41:1053-6. Erratum in: Clin Infect Dis. 2005;41:1694.
10. Kloosterboer N, Paul H, Jansen C, et al. Natural controlled HIV infection: Preserved HIV-specific immunity despite undetectable replication competent virus. Virology. 2005;339:70-80.
11. Wang B, Dyer W, Zaunders J, et al. Comprehensive analyses of a unique HIV-1-infected nonprogressor reveal a complex association of immunobiological mechanisms in the context of replication-incompetent infection. Virology. 2002;304:246-64.
12. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on HAART. Science. 1997;278:1295-300.
13. Greenough T, Brettler D, Kirchhoff F, et al. Long-term nonprogressive infection with HIV-1 in a hemophilia cohort. J Infect Dis. 1999;180:1790-802.
14. Zaunders J, Dyer W, Wang B, et al., Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. Blood. 2004; 103:2238-47.
15. Viard J, Burgard M, Hubert J, et al. Impact of 5 years of maximally successful HAART on CD4 cell count and HIV-1 DNA level. AIDS. 2004;18:45-9.
16. Rouzioux C, Hubert J, Burgard M, et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis. 2005;192:46-55.
17. Candotti D, Costagliola D, Joberty C, et al. Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. French ALT Study Group. J Med Virol. 1999;58:256-63.
18. Rodes B, Toro C, Paxinos E, et al. Differences in disease progression in a cohort of long-term nonprogressors after more than 16 years of HIV-1 infection. AIDS. 2004;18:1109-16.
19. Koot M, Keet I, Vos A, et al, Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med. 1993;118:681-8.
20. Wang B, Lal R, Dwyer D, et al., Molecular and biological interactions between two HIV-1 strains from a coinfected patient reveal the first evidence in favor of viral synergism. Virology. 2000;274:105-19.
21. Masciotra S, Owen S, Rudolph D, et al. Temporal relationship between V1V2 variation, macrophage replication, and coreceptor adaptation during HIV-1 disease progression. AIDS. 2002;16:1887-98.
22. Wang Y, Dyer W, Workman C, et al. Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption and non-interrupted HAART. Curr HIV Res. 2007;5:235-50.
23. Wang Y, Wang B, Dyer W, et al. Evidence for predominance of CCR5-using HIV-1 strains during HAART. Curr HIV Res. 2007;5:221-34.
24. Mellors J, Kingsley L, Rinaldo C, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122:573-9.
25. Conner R, Ho D. HIV type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol. 1994;68:4400-8.
26. + lymphocytes. Proc Natl Aca Sci USA. 1994; 91:1104-8.
27. + T-cell number decline in HIV type 1-infected individuals. J Virol. 1995;69:2092-100.
28. + T-lymphocyte decline and clinical progression in HIV type 1-infected individuals. J Virol. 1993; 67:1772-7.
29. Gurusinghe A, Land S, Birch C, et al. Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS. J Med Virol. 1995;46:238-43.
30. Wang B, Ge Y, Palasanthiran P, et al. Gene defects clustered at the C-terminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pair: in vivo evolution of vpr quasispecies in blood and plasma. Virology. 1996;223:224-32.
31. Kirchhoff F, Easterbrook P, Douglas N, et al. Sequence variations in HIV-1 Nef are associated with different stages of disease J Virol. 1999;73:5497-508.
32. Cao Y, Qin L, Zhang L, Safrit J, Ho D. Virologic and immunologic characterization of long-term survivors of HIV-1 infection. N Engl J Med. 1995;332:201-8.
33. Barker E, Mackewicz C, Reyes-Teran G, et al. Virologic and immunologic features of long-term HIV-infected individuals who have remained asymptomatic compared with those who have progressed to AIDS. Blood. 1998;92:3105-14.
34. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive HIV infection. N Engl J Med. 1995;332:209-16.
35. O'Brien T, Blattner W, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996;276:105-10.
36. Bello G, Casado C, Sandonis V, et al. Plasma viral load threshold for sustaining intrahost HIV type 1 evolution. AIDS Res Hum Retroviruses. 2007;23:1242-50.
37. Nowak M, Anderson R, McLean A, Wolfs T, Goudsmit J, May R. Antigenic diversity thresholds and the development of AIDS. Science. 1991;254:963-9.
38. Kohler H, Goudsmit J, Nara P. Clonal dominance: cause for a limited and failing immune response to HIV-1 infection and vaccination. J Acquir Immune Def Syndr. 1992;5:1158-68.
39. Shankarappa R, Margolick J, Gange S, et al. Consistent viral evolutionary changes associated with the progression of HIV-1 infection. J Virol. 1999;73:10489-502.
40. Wang B, Ge Y, Jozwiak R, et al. Molecular analyses of HIV-1 V3 region quasispecies derived from plasma and PBMC of the first long-term nonprogressing mother and child pair. J Infect Dis. 1997;175:1510-5.
41. Lukashov V, Kuiken C, Goudsmit J. Intrahost HIV type 1 evolution is related to length of the immunocompetent period. J Virol. 1995;69:6911-6.
42. Ross H, Rodrigo A. Immune-mediated positive selection drives HIV-I molecular variation and predicts disease duration. J Virol. 2002;76:11715-20.
43. Saksena N. Human Immunodeficiency Viruses: Biology, Immunology and Molecular Biology. Saksena NK (ed). Genoa, Italy: Medical systems spA 1998.
44. Churchill M, Chiavaroli L, Wesselingh S, Gorry P. Persistence of attenuated HIV-1 rev alleles in an epidemiologically linked cohort of long-term survivors infected with nef-deleted virus. Retrovirology. 2007;4:43.
45. Caly L, Wang B, Mikhail M, et al. Evidence for host-driven selection of the HIV type 1 vpr gene in vivo during HIV disease progression in a transfusion-acquired cohort. AIDS Res Hum Retroviruses. 2005;21:728-33.
46. Zhao Y, Chen M, Wang B, et al. Molecular and functional dynamics of naturally occurring HIV-1 Vpr gene mutations and its and its possible association with disease progression in long-term non-progressing motherchild pair. Virus Res 2002;89;103-21.
47. Mariani R, Kirchhoff F, Greenough T, et al. High frequency of defective nef alleles in a long-term survivor with non-progressive HIV-1 infection. J Virol. 1996;70:7752-64.
48. Rhodes D, Ashton L, Solomon A, et al. Characterization of three nef-defective HIV-1 strains associated with long-term nonprogression. Australian Long-Term Nonprogressor Study Group. J Virol. 2000;74:10581-8.
49. Kirchhoff F, Greenough T, Brettler D, Sullivan J, Desrosiers R. Brief report: absence of intact nef sequences in a long-term survivor with non-progressive HIV-1 infection. N Engl J Med. 1995;332:228-32.
50. Binley J, Jin X, Huang Y, et al. Persistent antibody responses but declining cytotoxic T-lymphocyte responses to multiple HIV-1 antigens in a long-term nonprogressing individual with a defective p17 proviral sequence and no detectable viral RNA expression. J Virol. 1998;72:3472-4.
51. Roman F, Karita E, Monnet A, et al. Rare and new V3 loop variants in HIV-1-positive long-term non-progressors from Rwanda. AIDS. 2002;16:1827-9.
52. Mikhail M, Bin Wang, Lemey P, et al. Role of viral evolutionary rate in HIV disease progression in a linked cohort. Retrovirology. 2005;2:41.
53. Sivakumaran H, Wang B, Gill M, Beckholdt B, Saksena N, Harrich D. Functional relevance of non-synonymous mutations in the HIV-1 tat gene within an epidemiologically-linked transmission cohort. Virol J. 2007;4:107.
54. Michael N, Chang G, D'Arcy L, et al. Functional characterization of HIV-1 nef genes in patients with divergent rates of disease progression. J Virol. 1995;69:6758-69.
55. Borman A, Quillent C, Charmeau P, Kean K, Clavel F. A highly defective HIV-1 group O provirus: evidence for the role of local sequence determinants in G-A hypermutation during negative- strand viral DNA synthesis. Virology. 1995;208:601-9.
56. Fitzgibbon J, Mazar S, Dubin T. A new type of G-A hypermutation affecting HIV. AIDS Res Hum Retroviruses. 1993;9:833-8.
57. + T-cells. J Virol. 2001;75:7973-86.
58. + T-cells in vivo. J Virol 2004; 79:1975-80.
59. Liu Y, Tang X, McArthur J, Scott J, Gartner S. Analysis of HIV-1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J Neurovirol. 2000;6(Suppl 1):S70-81.
60. Monken C, Wu B, Srinivasan A. High resolution analysis of HIV-1 quasispecies in the brain. AIDS. 1995;9:345-9.
61. Wei M, Xing H, Hong K, et al. Biased G-to-A hypermutation in HIV-1 proviral DNA from a long-term nonprogressor. AIDS. 2004;18:1863-5.
62. Harris R, Bishop N, Sheehy A, et al. DNA deamination mediates innate immunity to retroviral infection. Cell. 2003;113:803-9.
63. Zhang H, Yang B, Pomerantz R, Zhang C, Arunachalam S, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2004;424:94-8.
64. An P, Bleiber G, Duggal P, et al. APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol. 2004;78:11070-6.
65. Jin X, Brooks A, Chen H, et al. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with HIV viremia. J Virol. 2005;79:11513-16.
66. + T-cell count. J Virol. 2006;80:2069-72.
67. Rey D, Vidinic-Moularde J, Meyer P, et al. High prevalence of GB virus C/ hepatitis G virus RNA and antibodies in patients infected with HIV-1. Eur J Clin Microbiol Infect Dis. 2000;19:721-4.
68. Sathar M, York D, Gouws E, Coutsoudis A, Coovadia H. GB virus type C coinfection in HIV-infected African mothers and their infants, KwaZulu Natal, South Africa. Clin Infect Dis. 2004;38:405-9.
69. Tillmann H, Heiken H, Knapik-Botor A, et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med. 2001;345:715-24.
70. Williams C, Klinzman D, Yamashita T, et al. Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med. 2004;350:981-90.
71. + T-lymphocyte cell line. J Gen Virol. 2007;88:3341-6
72. + Jurkat T-cells. Proc Natl Acad Sci USA. 2006;103:15570-5.
73. Berzsenyi M, Bowden D, Roberts S. GB virus C: insights into coinfection. J Clin Virol. 2005;33:257-66.
74. Xiang J, George S, Wunschmann S, et al. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1α, MIP-1β, and SDF-1. Lancet 2004;363:2040-6.
75. Pomerantz R, Nunnari G. HIV and GB virus C-can two viruses be better than one? N Engl J Med. 2004;350:963-5.
76. Descamps D, Damond F, Benard A, et al. No association between GB virus C infection and disease progression in HIV-2-infected patients from the French ANRS HIV-2 cohort. AIDS. 2006;20:1076-9.
77. Van der Bij A, Kloosterboer N, Prins M, et al. GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study. J Infect Dis. 2005;191:678-85.
78. Rockstroh J. Influence of viral hepatitis on HIV infection. J Hepatol. 2006;44:25-7.
79. Belike M, Theall K, O'Brien M, et al. Clinical outcomes and disease progression among patients coinfected with HIV and human T lymphotropic virus types 1 and 2. Clin Infect Dis. 2004;39:256-63.
80. Turci M, Pilotti E, Ronzi P, et al. Coinfection with HIV-1 and human T-Cell lymphotropic virus type II in intravenous drug users is associated with delayed progression to AIDS. J Acquir Immune Defic Syndr. 2006;41:100-6.
81. + TF-1 cells through activation of STAT1 and STAT5 by secretion of IFNγ and granulocyte macrophage-colony-stimulating factor. Blood. 2002;99:224-31.
82. Pilotti E, Elviri L, Vicenzi E, et al. Postgenomic upregulation of CCL3L1 expression in HTLV-2-infected persons curtails HIV-1 replication. Blood. 2007;109:1850-6.
83. Bassani S, Lopez M, Toro C, et al. Influence of HTLV-2 coinfection on virologic and immunologic parameters in HIV-1-infected patients. Clin Infect Dis. 2007;44:105-10.
84. Norrgren H, Andersson S, Biague A, et al. Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, West Africa: no protection of HIV-2 against HIV-1 infection. AIDS. 1999;13:701-7.
85. Wiktor S, Nkengasong J, Ekpini E, et al. Lack of protection against HIV-1 infection among women with HIV-2 infection. AIDS. 1999;13:695-9.
86. Arien K, Abraha A, Quinones-Mateu M, et al. The replicative fitness of primary HIV-1 group M, HIV-1 group O, and HIV-2 isolates. J Virol. 2005; 79:8979-90.
87. Leligdowicz A, Yindom L-M, Onyango C, et al. Robust Gag-specific T cell responses characterize viremia control in HIV-2 infection. J Clin Invest. 2007;117:3067-74.
88. Duvall M, Jaye A, Dong T, et al. Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection. J Immunol. 2006; 176:6973-81.
89. Cavaleiro R, Brunn G, Albuquerque A, et al. Monocyte-mediated T cell suppression by HIV-2 envelope proteins. Eur J Immunol. 2007;37:3435-44.
90. Zaunders J, Dyer W, Churchill M, et al. Clearance of transfusion acquired, attenuated nef-deleted HIV-1 infection by a LTNP with heterozygous CCR5 and HLA-B57 genotype. IAS, Sydney, Australia, July 2007 [abstract MOPEA 025].
91. + cell levels. J Infect Dis. 1994;170:775-81.
92. + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:83-92.
93. Zaunders J, Cunningham P, Kelleher A, et al. Potent antiretroviral therapy of primary HIV-1 infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis. 1999;180:320-9.
94. Kelleher A, Carr A, Zaunders J, Cooper D. Alterations in the immune response of HIV-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis. 1996;173:321-9.
95. + T-cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-16.
96. + lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. AIDS. 1998;12:1267-73.
97. + T-cell subsets in HIV-infected rapid progressor children versus non-rapid progressor children. J Allergy Clin Immunol. 2001;108:258-64.
98. Fahey J, Taylor J, Detels R, et al. The prognostic value of cellular and serologic markers in infection with HIV-1. N Engl J Med. 1990;322:166-72.
99. + T-cells and T-cell activation markers in HIV-1 infected children on HAART. Clin Exp Immunol 2001;125:266-73.
100. Wu J, Wang B, Belov L, et al. Antibody microarray analysis of cell surface antigens on CD4+ and CD8+ T cells from HIV+ individuals correlates with disease stages. Retrovirology. 2007;4:83.
101. Tarazona R, DelaRosa O, Casado J, et al. NK-associated receptors on CD8 T cells from treatment-naive HIV-infected individuals: defective expression of CD56. AIDS. 2002;16:197-200.
102. Sheeter D, Du P, Rought S, Richman D, Corbeil J. Surface CD4 expression modulated by a cellular factor induced by HIV type 1 infection. AIDS Res Hum Retroviruses. 2003;19:117-23.
103. Corbeil J, Sheeter D, Genini D, et al. Temporal gene regulation during HIV-1 infection of human CD4+ T cells. Genome Res. 2001;11:1198-204.
104. + T-Cells. Virol. 2007;81:3477-86.
105. Girl M, Nebozhyn M, Showe L, Montaner L. Microarray data on gene modulation by HIV-1 in immune cells: 2000-2006. J Leukoc Biol. 2006;80:1031-43.
106. Harrer T, Harrer E, Kalams S, et al. Cytotoxic T-lymphocytes in asymptomatic long-term non-progressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol. 1996;156:2616-23.
107. Harrer T, Harrer E, Kalams S, et al. Strong cytotoxic T-cell and weak neutralizing antibody responses in a subset of persons with stable non-progressing HIV type 1 infection. AIDS Res Hum Retroviruses. 1996;12:585-92.
108. Kaslow R, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV- 1 infection. Nat Med. 1996;2:405-11.
109. Keet I, Tang J, Klein M, et al. Consistent associations of HLA class I and II and transporter gene products with progression of HIV type 1 infection in homosexual men. J Infect Dis. 1999;180:299-309.
110. Plummer F, Ball T, Kimani J, Fowke K. Resistance to HIV-1 infection among highly exposed sex workers in Nairobi: what mediates protection and why does it develop? Immunol Lett. 1999;66:27-34.
111. Tomiyama H, Miwa K, Shiga H, et al. Evidence of presentation of multiple HIV-1 cytotoxic T-lymphocyte epitopes by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS. J Immunol. 1997;158:5026-34.
112. Carrington M, Nelson G, Martin M, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science. 1999; 283:1748-52.
113. Klein M, Van der Burg S, Hovenkamp E, et al. Characterization of LA-B57-restricted HIV type 1 Gag- and RT-specific cytotoxic T lymphocyte esponses. J Gen Virol. 1998;79:2191-201.
114. Migueles S, Sabbaghian M, Shupert W, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long-term nonprogressors. Proc Natl Acad Sci USA. 2000;97:2709-14.
115. Migueles S, Laborico A, Shupert W, et al. HIV-specific CD8+ T-cell proliferation is coupled to perforin expression and is maintained in non-progressors. Nat Immunol. 2002;3:1061-8.
116. Hendel H, Caillat-Zucman S, Lebuanec H, et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol. 1999;162:6942-6.
117. Scherer A, Frater J, Oxenius A, et al. Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS. Proc Natl Acad Sci USA. 2004;101:12266-70.
118. Leslie A, Pfafferott K, Chetty P, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med. 2004;10:282-9.
119. Kiepiela P, Leslie A, Honeyborne I, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature. 2004; 432:769-75.
120. Fellay J, Shianna K, Ge D, et al., A whole-genome association study of major determinants for host control of HIV-1. Science 2007;317:944-7.
121. de Bakker P, Burtt N, Graham R, et al. Transferability of tag SNPs in genetic association studies in multiple populations. Nat Genet. 2006;38:1298-303.
122. Altfeld M, Addo M, Rosenberg E, et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS. 2003; 17:2581-91.